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Abstract: Genomic deoxyribonucleic acid (DNA) is under constant threat from endogenous 
and exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA 
repair machinery to process DNA damage and maintain genomic integrity. Impaired DNA repair 
is a major driver for carcinogenesis and could promote aggressive cancer biology. Interestingly, 
in established tumors, DNA repair activity is required to counteract oxidative DNA damage that 
is prevalent in the tumor microenvironment. Emerging clinical data provide compelling evidence 
that overexpression of DNA repair factors may have prognostic and predictive significance in 
patients. More recently, DNA repair inhibition has emerged as a promising target for anticancer 
therapy. Synthetic lethality exploits intergene relationships where the loss of function of either 
of two related genes is nonlethal, but loss of both causes cell death. Exploiting this approach 
by targeting DNA repair has emerged as a promising strategy for personalized cancer therapy. 
In the current review, we focus on recent advances with a particular focus on synthetic lethality 
targeting in cancer.
Keywords: biomarker, drug target, synthetic lethality
Introduction
Genomic deoxyribonucleic acid (DNA) is at risk of damage from endogenous metabolic 
byproducts, spontaneous base modifications, and exogenous sources such as ultraviolet 
(UV) light, ionizing radiation, and chemical agents. Unrepaired DNA damage is a 
major source of potentially mutagenic lesions that drive carcinogenesis. To promote 
genomic stability, mammalian cells have evolved highly conserved DNA damage 
sensor mechanisms that can initiate: 1) induction of apoptosis to eliminate heavily 
damaged cells; 2) transcriptional response, which causes changes in the transcriptional 
profile that may promote cell survival; 3) DNA damage tolerance; 4) activation of 
DNA damage checkpoints and modulation of cell-cycle progression to allow time for 
DNA repair; and/or 5) initiation of DNA repair to restore genomic stability.
DNA repair pathways are so essential that germline mutations within DNA repair 
genes are associated with cancer predisposition syndromes such as hereditary non-
polyposis carcinoma coli (HNPCC) or breast cancer susceptibility protein (BRCA)-
deficient breast and ovarian cancer syndromes.1,2 In addition, polymorphic variants that 
confer suboptimal DNA repair capacity could also influence cancer susceptibility and 
prognosis.3,4 Furthermore, the anticancer activity of chemotherapy (such as alkylating 
agents and platinum compounds) and radiotherapy is to a large extent directly related 
to their ability to induce DNA damage. The DNA repair capacity of cancer cells to 
recognize and repair chemo/radiotherapy-induced damage is therefore also an  important 
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mechanism for therapeutic resistance that negatively impacts 
upon clinical outcomes.5 Pharmacological inhibition of DNA 
repair may increase cytotoxicity of anticancer agents, reverse 
treatment resistance and improve therapeutic efficacy.6 
Recent evidence indicates that inhibitors of DNA repair also 
offer the opportunity to target genetic differences that exist 
between normal and tumor tissue.7,8
In the current review, we provide an overview of major 
DNA repair pathways in mammalian cells. We will then focus 
on the emerging DNA repair drug targets for personalized 
cancer therapy.
DNA repair pathways
DNA repair pathways operate in mammalian cells to 
maintain genomic integrity (Figure 1). Loss of efficiency of 
one or more DNA repair mechanisms, whether by germline 
inheritance or sporadic mutation, accelerates the rate of 
accumulation of additional mutations by 100–1,000 times, 
with selective pressure favoring those mutations that drive 
carcinogenesis – the “mutator phenotype”.9,10
Direct repair
A number of mechanisms exist to directly reverse certain 
DNA-damage lesions in single-step processes. Direct reversal 
of the oxidative lesion O6-methylguanine is carried out by the 
suicide enzyme methylguanine methyltransferase (MGMT) 
via an active site Cys145 that acts as a methyl recipient, 
followed by rapid ubiquitin-induced degradation. MGMT 
expression is one of several factors governing response to 
alkylating chemotherapy agents.11,12 The 2-oxoglutarate/iron-
dependent dioxygenases, alkylated DNA repair protein alkB 
homolog 2 (ABH2) and alkylated DNA repair protein alkB 
homolog 3 (ABH3) also repair various alkylation adducts, 
including 1-methyladenine and 1-ethyladenine, by oxidative 
dealkylation. ABH2 preferentially acts on double-stranded 
DNA, possibly in the vicinity of replication forks, whereas 
ABH3 is involved in single-stranded DNA and ribonucleic 
acid (RNA) repair.11 ABH2 and ABH3 knockout mice are 
viable with no cancer phenotype, although ABH2-deficient 
mice do spontaneously accumulate 1-methyladenine adducts 
and are hypersensitive to exogenous alkylating agents.13 
UV-induced damage such as cyclobutane pyrimidine dim-
ers (CPDs) and pyrimidine (6-4) pyrimidone photoproducts 
(6-4PPs) are repaired via photolyases: 50–55 kDa flavo-
proteins that contain chromophoric groups (flavin adenine 
dinucleotides) that become activated when illuminated with 
visible or near-UV light, allowing transfer of an electron to 
the lesion to destabilize the interpyrimidine bonds.14
Base excision repair
Base excision repair (BER) is responsible for detection 
and repair of damage caused by a number of mechanisms, 
including alkylation, oxidation, ring saturation, single-strand 
breaks (SSBs), and base deamination. Although complex, 
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Figure 1 Types of DNA damage and DNA repair pathways. 
Abbreviation: DNA, deoxyribonucleic acid.
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with at least two subpathways (short patch and long patch), 
BER generally proceeds via: 1) recognition and removal of 
a damaged base by a DNA glycosylase to form an apurinic/
apyrimidinic (AP) site intermediate, 2) cleavage of the phos-
phodiester backbone 5′ to the AP site by AP endonuclease 1 
(APE1), 3) removal of the 5′ sugar fragment, 4) incorporation 
of the correct base by a DNA polymerase, and 5) sealing 
of the strand break by a DNA ligase (Figure 1).14–21 Given 
the wide range of substrate lesions and potential mutagenic 
sequelae of failed repair, several BER gene mutations have 
been linked to human disease, including autosomal recessive 
familial adenomatous polyposis (MYH mutation), primary 
immunodeficiency disorders (uracil DNA glycosylase muta-
tion), and neurological disorders (mutations in auxiliary 
genes such as aprataxin, tyrosyl-DNA phosphodiesterase 
1, or polynucleotide kinase 3′-phosphatase). Furthermore, 
large numbers of single-nucleotide polymorphisms in BER 
genes have been identified, with variable effect on repair 
capacity and pathological consequences (reviewed in Wilson 
et al).22
SSB repair
SSB repair (SSBR) is most accurately considered a BER-
related pathway, given the similarity of substrates and shared 
protein members. SSBR repairs single-strand discontinuities 
arising from a variety of sources, including reactive oxygen 
species (ROS), base deamination, and BER intermediates. 
It also repairs breaks introduced by DNA topoisomerase 
1 (topo I) activity, which transiently introduces a DNA 
nick to relax DNA during transcription and replication, 
but which can fail to reseal the nick if in close proximity 
to polymerases or other DNA lesions.23,24 SSBR requires 
effective surveillance and damage detection, for which 
PARP1 (poly[ADP-ribose] polymerase 1) is believed to 
play an essential role. On detecting an SSB, PARP1 rapidly 
becomes bound and poly(ADP-ribosyl)ated, protecting the 
nick ends from undesirable recombination and allowing the 
recruitment of the molecular scaffold protein X-ray repair 
cross-complementing protein 1 (XRCC1) for ongoing repair. 
As with BER, end processing follows damage recognition and 
may be undertaken by a large range of proteins (depending 
upon the termini damage present), each of which requires 
interaction with XRCC1 for efficient activity. ROS-related 
damage often results in 3′-phosphate and 3′-phosphoglyco-
late modifications, which are processed by polynucleotide 
kinase (PNK) 3′-phosphatase (PNKP) and APE1 respec-
tively. Topo I-associated SSBs require processing by TDP1 
(tyrosyl-DNA phosphodiesterase 1), whereas 5′-adenosine 
monophosphate-SSBs resulting from abortive DNA ligase 
activity at existing SSBs are processed by aprataxin. Repair 
can then proceed via short- or long-patch gap filling and 
end ligation as in the classical BER pathway.25 SSBR may 
also play a role in replication-associated damage repair.25,26 
When the replication machinery encounters an unrepaired 
SSB, fork collapse occurs, with the creation of a one-ended 
double-strand break (DSB) on one chromatid, and an SSB 
on the other. The DSB is processed by components of the 
homologous recombination (HR) pathway to allow RAD51-
mediated template switching and reformation of the repli-
cation fork. Without repair, the associated SSB would be 
converted to a further DSB on replication fork restart, and 
hence would represent an irrevocably unrepairable lesion. 
SSBR end-processing and long-patch BER are probably 
involved in replication-coupled SSBR, as highlighted by 
the transcriptional activation of the critical SSBR enzyme 
XRCC1 by replication-associated transcription factors, such 
as forkhead box protein M1 (FOX M1) and E2F-1.27,28
Nucleotide excision repair
Nucleotide excision repair (NER) recognizes and repairs 
base lesions associated with distortion of the DNA helical 
structure, including UV-induced photoproducts not elimi-
nated by direct repair, and an array of bulky adducts induced 
by various exogenous chemical agents. Two subpathways of 
NER exist: global genome NER (GG-NER) and transcrip-
tion-coupled NER (TC-NER). TC-NER removes lesions 
from the transcribed DNA strand of transcriptionally active 
genes when encountered by RNA polymerase II, restoring 
transcriptional activity and preventing apoptosis. GG-NER 
performs this process with poor efficiency, instead removing 
lesions on non-transcribed strands and transcriptionally inert 
genes to avoid replication fork stalling and chromosomal 
breakages.29 In GG-NER, damage recognition is sensed by 
various proteins, including the xeroderma pigmentosum 
(XP), complementation group C (XPC)-RAD23B complex 
(helix distortions), UV-damaged DNA-binding protein 1 
(DDB1), and UV-damaged DNA-binding protein 2 (DDB2) 
(UV damage), and XPA (unknown substrate).30 In TC-NER, 
recognition is mediated by stalling of RNA polymerase 
II at a damaged site. Recognition factor binding in both 
pathways is associated with localized distortion to allow 
repair factor access to the damaged site. Transcription fac-
tor IIH (TFIIH), a nine-subunit complex including the DNA 
helicases XP complementation group B (XPB) and XP 
complementation group D (XPD), is recruited to unwind 
the DNA local to the damaged site. Dual incision around 
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the lesion is performed by structure-specific endonucleases 
XP complementation group G (XPG) (3′ incision) and the 
excision repair  cross-complementing group 1 (ERCC1)-XP 
complementation group F (XPF) complex (5′ incision), 
resulting in cleavage of a 24–29 nucleotide fragment. In com-
mon with BER and mismatch repair (MMR), proliferating 
cell nuclear antigen (PCNA) is then recruited to coordinate 
DNA polymerase repair synthesis and DNA ligase nick 
joining.29 Given the critical role NER plays in repairing UV-
induced damage, it is unsurprising that mutation within NER 
genes can lead to UV hypersensitivity. XP is an autosomal 
recessive syndrome that manifests as photosensitivity, neu-
rological abnormalities, and predisposition to skin and other 
cancers. XP is characterized by marked clinical and genetic 
heterogeneity, with causative mutations falling into one of 
seven complementation groups that span many NER factors. 
Different mutations in the same NER genes can give rise to 
alternative phenotypes that do not include cancer predisposi-
tion, namely Cockayne syndrome (variable UV sensitivity, 
premature aging, and physical and mental retardation) and 
trichothiodystrophy (TTD; variable UV-sensitivity, prema-
ture aging, ichthyosis, brittle hair, and short stature).31 This 
heterogeneity may result from the bifunctionality of NER 
factors. For example, the XPD complementation group is 
associated with several disease-specific mutations that may 
cause XP, combined Cockayne syndrome and XP, or TTD. 
When the causative mutation is associated with XP, the NER 
function of TFIIH is deficient, correlating with a phenotype of 
severe UV-sensitivity and cancer predisposition. TFIIH also 
has a role in transcriptional initiation of RNA polymerase II, 
in which the helicase subunits (XPB and XPD) unwind the 
DNA at the promoter region to allow transcription complex 
access. XPD mutations affecting this function may have 
normal NER (non-UV-sensitive TTD), or defective CPD but 
intact 6-4PP repair (UV-sensitive TTD), accounting for the 
reduced malignancy risk.
MMR
MMR recognizes and repairs errors introduced during rep-
lication. DNA polymerases possess 3′-5′ exonuclease activ-
ity to excise incorrectly paired bases in newly synthesized 
DNA. Failure of this proofreading process leads to mispair 
persistence, forming a substrate for MMR. MMR also 
recognizes and repairs insertion/deletion loops (IDLs), par-
ticularly within microsatellite DNA – hence, “microsatellite 
instability” is recognized as a hallmark of MMR failure.32,33 
If microsatellite instability manifests within tumor sup-
pressor genes, it can produce frame-shift mutations that 
contribute to carcinogenesis – a common feature of certain 
cancers, including colorectal, endometrial, ovarian, and 
gastric cancer (reviewed in Li).34 MMR error recognition is 
initiated by heterodimers of MSH (Escherichia coli MutS 
homolog) ATPases. MutSα comprises MSH2 and MSH6, 
and recognizes base mismatches and small 1-2 nucleotide 
IDLs. MutSβ, comprising MSH2 and MSH3, binds to larger 
IDLs of up to 16 nucleotides. Loss of MSH2 results in the 
absence of both MMR subpathways, and hence cancer pre-
disposition in preclinical models35 and in the clinical setting 
(as HNPCC).36 Once bound to the DNA substrate, the MutS 
heterodimer recruits MutLα, a heterodimer comprised of 
MutL homolog 1 (MLH1) and PMS2, homologs of the E. coli 
ATPase MutL. MLH1 is critical to MMR, with deletion or 
promoter methylation producing a comparable phenotype to 
MSH2 mutation.37,38 The MutS/MutL complex functions as a 
sliding clamp, undergoing an ATP-dependent conformational 
change that results in release from the mismatch site fol-
lowed by translocation in both directions from the mismatch. 
Translocation continues until a strand break is encountered, 
such as the 3′ terminus of the leading strand, or the 5′ or 3′ 
termini of Okazaki fragments (200–1,000 nucleotide lag-
ging strand fragments generated and later ligated during 
replication). Exonuclease-1 (EXO1) is loaded at the strand 
break and degrades the strand back towards the mismatch 
site, allowing repair using the parent strand template by the 
high fidelity DNA polymerase δ (Polδ). DNA ligase I seals 
the gap.33,34
Non-homologous end joining
Along with HR repair, non-homologous end-joining is one of 
the two major pathways that exist for repair of DSBs. Non-
homologous end joining (NHEJ) essentially involves processing 
of the terminal nucleotides to allow end ligation, in a manner 
that restores molecular integrity but may not maintain sequence 
fidelity. Damage recognition in NHEJ is performed by the 
Ku70/Ku80 heterodimer, which binds to the DSB ends with 
high affinity, possibly tethering the broken ends together. Ku 
binding recruits and activates the DNA-dependent protein kinase 
DNA-PKcs, forming the DNA-PK complex that phosphorylates 
other repair proteins including XRCC4-like factor (XLF, also 
known as Cernunnos), Werner syndrome helicase (WRN), DNA 
ligase IV (LIG4), and XRCC4.  Additionally, DNA-PK is able 
to autophosphorylate, allowing NHEJ regulation. DNA end-
processing prepares damaged terminal nucleotides for ligation. 
Dependent on the nature of the damage, this may require variable 
combinations of repair factors.  Damaged DNA overhangs can 
be removed by nucleases such as Artemis, while other factors 
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such as WRN, PNK, and aprataxin and PNK-like factor also 
have roles. Nucleotide incorporation by DNA polymerases λ 
and µ replaces nucleotides cleaved during end-processing in 
a non-template dependent manner, and represents a significant 
source of error in the pathway. Once processed, ends are ligated 
by the LIG4/XRCC4/XLF complex.39–41
NHEJ is able to resolve a large variety of DNA DSB 
damage, and is thought to be the major pathway for DSB 
repair in eukaryotes, occurring throughout the cell cycle. 
Accurate repair in NHEJ is likely if the DSB possesses fully 
complementary single-stranded ends. In the absence of com-
plementary ends, repair is dependent on annealing of short 
microhomologous sequences (four or fewer nucleotides) 
within the overhanging ends, which leads to the introduction 
of potentially mutagenic deletions or insertions.42 NHEJ also 
has a critical role in V(D)J recombination to recombine the 
variable region in B-cell and T-cell receptors – in this context, 
low fidelity is beneficial to maximize diversity.43
Microhomology-mediated  
end joining
The observation that NHEJ can proceed in the absence of 
key factors, including DNA-PKcs and Ku, without signifi-
cant input from the HR pathway, has led to the theory that at 
least one backup NHEJ pathway exists.44 It appears that this 
pathway functions when classical NHEJ fails, either due to 
enzymatic deficiency or failure to interact at certain DNA 
lesions. This alternate mechanism, known as microhomology-
mediated end joining (MMEJ), is reliant on the annealing of 
microhomologous regions of 5–25 base pairs. To uncover 
these microhomologies, binding of the NHEJ heterodimer 
Ku and the HR factor RAD51 must be inhibited, possibly 
by members of the PARP family, to allow 5′-3′ nucleolytic 
resection by the MRN complex (MRE11-RAD50-NBS1). 
During this process, replication protein A (RPA) binds to 
the single-stranded DNA ends to prevent self-complemen-
tization. Once microhomologous regions are uncovered, the 
DNA overhangs anneal. End processing proceeds as required, 
via XRF-ERCC1 flap cleavage and polymerase-mediated 
gap-filling. Ligation appears to involve DNA ligase I (LIG1) 
and III (LIG3).42,45 Unlike NHEJ, MMEJ is always associ-
ated with sequence loss and is therefore always mutagenic. 
Indeed, microhomologies can frequently be demonstrated at 
chromosome breakpoints in human cancer cells.45
Single-strand annealing
Like MMEJ, single-strand annealing also involves 3′ end 
resection to uncover homologous regions that can anneal 
directly under RAD52 control. The size of homologous repeat 
sequences utilized in single-strand annealing (such as ∼300 bp 
Alu repeats) requires more extensive end resection creating a 
large flap. Flap removal is catalyzed by RAD1/RAD10 nucle-
ases, under SAW1/SLX4 (single-strand annealing weakened 
1/structure-specific endonuclease subunit 4) guidance, result-
ing in a large deletion event. Significant sequence diversity 
within repeat elements probably suppresses this pathway to 
a relatively minor role in DSB repair.40,46–60
HR
HR utilizes a homologous DNA sequence as a template 
for DNA synthesis and gap filling to ensure error-free 
repair.40,46–60 For this reason, HR is the predominant mecha-
nism for DSB repair during cellular replication. Cell cycle 
control is exerted by a dependence on cyclin-dependent 
kinase activity, which is upregulated in S and G2 phases, 
although high levels in M phase are associated with HR sup-
pression due to concurrent BRCA2 phosphorylation. HR is 
also suppressed during G1, when use of the homologous chro-
mosome as a template would result in loss of heterozygosity. 
Pathway choice for DSB repair is probably also guided by 
the repair substrate. Two-ended DSBs formed by fracture of 
a duplex molecule can generally be accurately repaired by 
simple end ligation via the NHEJ pathway, which in mam-
malian cells is the predominant mechanism of repair of this 
type of damage.61 Conversely, one-ended DSBs occurring 
when a replication fork encounters an SSB or distorting 
base lesion require template-guided repair to prevent inap-
propriate annealing leading to large-scale rearrangements or 
insertions/deletions.
In general, HR requires: 1) damage recognition, 
2) end resection mediated by the MRN complex, 
3) RAD51-dependent homology-directed strand invasion and 
repair synthesis, 4) dissociation from the template strand, and 
5) end ligation. The classical model is synthesis-dependent 
strand annealing, which occurs at two-ended DSBs. Follow-
ing damage recognition, 3′ strand resection coordinated by 
the MRN complex occurs on both fractured strands. MRN 
interacts with CtIP (also known as RBBP8 [retinoblastoma 
binding protein 8]) to promote end resection and generate 
3′ single-strand DNA overhangs. These are bound by the 
protective RPA to prevent self-annealing. RAD51 binds the 
DNA ends, in combination with associated proteins including 
BRCA2, RAD52, RAD54, RAD54B, and the RAD51 paral-
ogs (RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3). 
The resultant nucleoprotein filament invades the sister chro-
matid or homologous chromosome to search for homologous 
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regions to form heteroduplex DNA. Polymerase η catalyzes 
3′ extension of the invading strand using the sister strand as 
a template. The non-template DNA strand is displaced into 
a D-loop, with a Holliday junction forming at the crossover 
between the hetero- and homoduplex DNA. This junction can 
slide along the DNA in either direction (“branch migration”), 
facilitated by numerous proteins (WRN, BLM, p53, RAD54, 
BLAP75, MSH2/MSH6) via mechanisms that are yet to be 
elucidated. Branch migration results in strand dissociation 
upon reaching the terminus of the invading strand. Once 
released, the newly synthesized strand anneals beyond the 
original breakpoint, where it is bound by RPA and RAD52 
to coordinate recruitment of factors involved in end process-
ing (eg, XPF/ERCC1 for flap removal), gap filling (by DNA 
polymerases) and end ligation (by DNA ligases). The repaired 
strand can then be used as a template for DNA synthesis on 
the non-invading strand. As a result, sequence information is 
copied from the template region into the breakpoint (“gene 
conversion”), potentially resulting in loss of heterozygosity. 
An alternative model theorizes the formation of a double 
Holliday junction through simultaneous strand invasion by 
both DSB 3′ ends, possibly as a mechanism for DSB repair 
during meiosis. Strand dissociation in this model requires 
cleavage at the Holliday junction. Depending on the orienta-
tion of cleavage, this might result in a crossover event, which 
could account for the large-scale sequence exchanges that 
can be demonstrated in meiotic cells.
It is now thought that the primary repair substrates for HR 
are one-ended DSBs formed by replication fork collapse at 
the site of an unrepaired SSB or base lesion. Repair of such 
lesions occurs by the break-induced replication pathway, 
which initially proceeds in a similar manner to two-ended 
DSB repair, with 3′ resection creating an overhang which 
invades the sister chromatid and anneals to a homologous 
region in a RAD51-mediated mechanism. Cleavage of the 
single Holliday junction restores the replication fork, allow-
ing replication to continue. Dependent on the orientation of 
Holliday junction cleavage, this mechanism can result in 
the leading strand template becoming ligated to the newly 
synthesized lagging strand, resulting in a sister chromatid 
exchange.
Evidence to support replication fork collapse as the 
primary substrate for HR is based upon comparison of the 
recombination products formed following repair of induced 
SSBs and spontaneous recombination events. Restriction 
endonuclease-induced two-ended DSBs result in short 
tract gene conversion events, consistent with the synthesis-
dependent strand annealing model of HR described above. In 
contrast, camptothecin exposure induces one-ended DSBs by 
stabilizing DNA–topo-I interactions to prevent re-ligation of 
topo I-induced SSBs, thus leading to replication fork collapse. 
Repair of camptothecin-induced damage results in sister 
chromatid exchanges and long tract gene conversions. Simi-
larly, impaired repair of SSBs in XRCC1- or PARP1-deficient 
cells, or following PARP inhibitor exposure, increases one-
ended DSB formation, associated with increased formation of 
γH2AX and RAD51 foci – markers of HR activity.8,62 Sponta-
neous recombination outcomes are more similar in spectrum 
to failed SSBR or camptothecin-related repair products than 
to those formed during the repair of endonuclease-induced 
two-ended DSBs, suggesting that replication fork collapse 
forms the primary repair substrate for HR.62
Crosslink repair
A number of DNA repair mechanisms play a role in the repair 
of interstrand crosslinks (ICLs), a highly toxic form of dam-
age that can stall and collapse replication forks, potentially 
leading to DNA rearrangement, mutation, or cell death. 
ICLs are cytotoxic at densities as low as 40 per cell, because 
they cause DNA distortion and prevent strand dissociation, 
impacting upon DNA synthesis and replication.63
Fanconi anemia (FA) is an autosomal recessive condi-
tion associated with predisposition to acute myelogenous 
leukemia and other malignancies, progressive bone marrow 
failure, short stature, and developmental delay. Fourteen 
complementation groups have been identified, with evidence 
suggesting that an FA core complex containing Fanconi ane-
mia, complementation group A (FANCA), FANCB, FANCC, 
FANCE, FANCF, FANCG, and FANCL localizes to DNA 
damage and activates FANCD2, which in turn co-localizes 
with BRCA1. Recent studies also implicate XPF mutations 
in FA.64,65 Given that FA is associated with hypersensitivity to 
crosslinking agents, it is believed that the genetic basis may be 
a defect in ICL repair, although much of the pathway remains 
to be elucidated. The covalent link of the ICL causes local-
ized DNA distortion and prevents replication-mediated DNA 
unwinding, leading to replication fork stalling. This is rec-
ognized by FANCM and associated proteins, which recruits 
the FA core complex and other repair proteins, including 
FANCD2-FANCI. The FA core complex possesses ubiquitin 
ligase activity, which monoubiquitinates FANCD2-FANCI, 
allowing interaction with Fanconi-associated nuclease 1 
(FAN1) and DNA polymerase ν (Polν, POLN). FAN1 has 
5′-3′ exonuclease and 5′-flap endonuclease activity, causing 
DNA cleavage (known as “unhooking”) alongside the ICL, 
converting the stalled replication fork into a one-ended DSB on 
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the sister chromatid. A number of other nucleases may medi-
ate DNA cleavage 3′ to the ICL, including MUS81-EME1, 
XPF-ERCC1, and SLX1-SLX4, thus excising the damaged 
region. PCNA is recruited, coordinating a switch to trans-
lesion synthesis (TLS) involving REV1 and DNA poly-
merase ζ to extend the nascent strand beyond the ICL site.66 
Subsequently, the 3′ strand of the sister chromatid DSB is 
reintegrated into the homologous duplex, forming a double 
Holliday junction, and replication is restarted via HR in a 
RAD51-dependent manner.67–70
DNA damage tolerance mechanisms
Unrepaired lesions (particularly bulky adducts, intercalations, 
crosslinks, and helix distortions) can block progression of the 
replication fork. DNA damage tolerance mechanisms allow 
the replication machinery to bypass these lesions prior to 
repair. This allows replication to proceed without affecting 
the viability of dividing cells, but can increase the risk of 
propagating mutations to the daughter population.71
The DNA polymerase-mediated TLS pathway may pro-
ceed by one of two models. In polymerase-switching TLS, 
fork progression is stalled when the replicative helicase 
encounters a DNA lesion. This triggers the recruitment of 
specialized TLS polymerases that insert one or more nucle-
otides opposite the damaged base before the replicative poly-
merase is “switched” back into the replication machinery. 
The alternative “gap-filling” TLS model involves reinitiation 
of replication downstream from the damage lesion, result-
ing in a single-strand gap that is filled by one of the TLS 
polymerases. Polymerases that have been implicated in TLS 
include Polν, Polθ (A family polymerases), Polζ (B family 
polymerase), Polβ, Polλ, Polµ, and terminal deoxynucleoti-
dyl transferase (X family polymerases), Polη, Polκ, Polι, and 
Rev1 (Y family polymerases). Polymerase choice may be 
damage-specific: for example, Polη may bypass UV-induced 
CPDs, whereas Rev1 may function in AP site bypass.72 TLS 
fidelity is polymerase-specific, highly variable, and may be 
an important source of genomic instability and susceptibility 
to cancer and other diseases.73
The HR pathway may also play a role in bypassing unre-
paired lesions during replication, via a subpathway known as 
template switching. In this mechanism, the stalled daughter 
strand invades the sister chromatid in an HR-mediated 
mechanism to utilize the complementary parent strand as a 
template for synthesis, creating a Holliday junction that is 
resolved prior to resumption of replication. An alternative 
HR-related model is that of fork regression. The presence 
of a single-strand base lesion blocks replication on one 
parent strand, whilst replication persists on the complemen-
tary strand beyond the point of damage. Regression of the 
replication fork allows transient annealing of the daughter 
strands into a Holliday intermediate (“chicken foot” struc-
ture), providing an alternative template for synthesis across 
the damaged region.74,75
Global DNA damage response
The cellular DNA damage response involves activation of cell 
cycle checkpoints to induce a cell cycle arrest while repair 
mechanisms, transcriptional modulation, and/or apoptotic 
pathways are activated. DNA damage is detected by sensor 
proteins, which may overlap with specific repair pathway 
damage sensors. Checkpoint-specific sensors include: ataxia 
telangiectasia mutated (ATM), which primarily detects DSBs; 
ataxia telangiectasia and Rad3 related (ATR), which detects 
UV-induced and other damage; and RAD17-replication factor 
C (RFC complex) in conjunction with the RAD9-RAD1-
HUS1 (9-1-1) complex, which can detect multiple damage 
types. Damage sensors interact with a wide range of media-
tor proteins, including BRCA1, MDC1 (mediator of DNA 
damage checkpoint 1), 53BP1 (p53 binding protein 1), and 
Claspin, which are required for downstream activation of 
Chk1 (activated downstream from ATR signaling) and Chk2 
(activated downstream from ATM signaling). Chk1 and -2 
kinases phosphorylate the phosphotyrosine phosphatases 
Cdc25A, -B, and -C, leading to their inactivation. As a result, 
the Cdc phosphatases are unable to dephosphorylate the 
cyclin-dependent kinases that promote cell cycle transition: 
Cdk2, which promotes the G1/S transition, and Cdc2 phos-
photyrosine, which promotes the G2/M transition.
Three main checkpoints exist: G1/S, intra-S phase, and 
G2/M. The G1/S checkpoint is activated by damage that 
prevents initiation of replication, via the ATM-Chk2-Cdc25A 
or ATR-Chk1-Cdc25A pathways, and is maintained by Chk1 
or Chk2-mediated phosphorylation of p53, which leads to 
p21-mediated inactivation of Cdk2. The intra-S phase check-
point is activated by replication fork stalling, and is probably 
initiated both by the specialized checkpoint sensors (via 
inactivation of the S phase promoters cyclin E/Cdk2) and by 
various repair proteins such as the MRN complex (MRE11/
RAD50/NBS1) and BRCA1. Activation by the latter group 
of sensors is thought to also activate a second pathway via 
phosphorylation of SMC1 (structure and maintenance of 
chromosomes 1) and SMC3 (structure and maintenance of 
chromosomes 3), which promotes recombination repair to 
recover stalled or collapsed replication forks. The G2/M 
checkpoint, which prevents initiation of mitosis in the 
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presence of DNA damage, operates via the ATM and ATR-
mediated to regulate G2/M transition via inactivation of 
Cdc25C/Cyclin B.14 Maintenance of the G2/M arrest requires 
transcriptional repression of Cdc2 and Cyclin B expression, 
mediated via activation of p53 and p21.
Activation of p53 plays an important role in apoptotic 
signaling. It has been implicated in activation of the intrinsic 
apoptosis pathway by shifting the balance of the multifunc-
tional B-cell lymphoma-2 (Bcl-2) family away from Bcl-2 
survival signaling towards induction of proapoptotic factors 
such as Bax and PUMA (p53 upregulated modulator of 
apoptosis), which contribute to caspase cascade activation.76 
Furthermore, p53 has been linked to activation of Fas and 
DR5/KILLER death receptors, which activate the extrinsic 
apoptosis pathway that also contributes to caspase-mediated 
cell death.77
Clinical implications of DNA  
repair in cancer
Alterations in expression of DNA repair may influence cancer 
biology and influence aggressive phenotypes. Germ-line 
polymorphism of the POLB gene (rs3136797) encoding a 
Polβ variant with a low catalytic activity has been recently 
shown to induce cellular transformation and may be asso-
ciated with increased cancer susceptibility.78 About 30% 
of human tumors appear to express Polβ variant proteins 
(such as K289M or I260M) which can induce cellular trans-
formation in vitro, associated with an aggressive mutator 
phenotype.79
Overexpression of DNA repair factors may promote cell 
survival in established tumors. For example, ROS generated 
during increased metabolic activity in cancer cells generate 
DNA damaging lesions such as AP sites, oxidative base dam-
age, DNA SSBs, and DNA DSBs. If unrepaired, such DNA 
lesions could be deleterious to the cancer cell. Moreover, 
hypoxic and acidic tumor microenvironments can promote 
further oxidative stress in cancer cells. Although ROS 
scavenging systems (such as glutathione and thioredoxin, 
superoxide dismutases, catalases, and peroxidases) do oper-
ate in cancer cells, capacity is limited, eventually leading 
to ROS-induced DNA damage. Therefore cancer cells also 
utilize the DNA repair machinery to process DNA damag-
ing lesions and maintain cellular survival. Clinical evidence 
supports the hypothesis that overexpression of DNA repair 
factors may have prognostic and predictive significance in 
patients (reviewed in Abbotts and Madhusudan).21
Taken together, this evidence suggests that targeting DNA 
repair is a valid anticancer strategy. A detailed discussion is 
beyond the scope of this article, as several recent comprehen-
sive reviews are available.80–83 Here, we focus on the current 
status of PARP inhibitors in cancer therapy.
The most advanced class of DNA repair inhibitors to date 
are PARP inhibitors, which disrupt the BER-related SSBR 
pathway. PARP1 senses and binds to DNA strand breaks, 
catalyzing (auto-) poly(ADP-ribosyl)ation of target proteins 
to induce localized chromatin relaxation and assembly of an 
XRCC1-LIG3-PNKP repair complex. A number of potential 
PARP inhibitors have been identified, usually with nonspeci-
ficity within the PARP family due to high sequence homology 
at the active site. In vitro and in xenograft models, PARP 
inhibitors have been demonstrated to potentiate the action of 
a wide variety of damaging agents, including platinums, the 
alkylating agents temozolomide and cyclophosphamide, the 
nucleoside analogue gemcitabine, the topoisomerase inhibitor 
irinotecan, and ionizing radiation.84,85 Several PARP inhibi-
tors have entered the clinical setting in Phase I–III studies in 
combination with various chemotherapeutic agents, although 
results have been mixed (reviewed recently by Davar et al).86 
For example, the Pfizer compound rucaparib (AG-014699; 
Pfizer, Inc., New York, NY, USA) has been evaluated in 
Phase I and II in combination with temozolomide in malig-
nant melanoma, demonstrating successful PARP inhibition 
at a tissue level and probable anticancer activity, but sig-
nificant myelosuppression causing dose-limiting toxicity.87 
Similar toxicity has been noted with olaparib (AZD2281; 
AstraZeneca, London, UK) in combination with paclitaxel, 
carboplatin, or cisplatin and gemcitabine in Phase III trials 
in gastric cancer.88  Myelosuppression or other dose-limiting 
toxicities have not been noted with iniparib (BSI-201; 
Sanofi, Paris, France), which has been evaluated at Phase 
II in metastatic triple-negative breast cancer in combination 
with gemcitabine and carboplatin. A significantly improved 
median overall survival was demonstrated compared with 
gemcitabine and carboplatin alone, without increased 
toxicity. However, a Phase III trial failed to meet co-primary 
endpoints of overall and progression-free survival,89 and after 
further disappointing results in a Phase III non-small-cell 
lung cancer trial, iniparib has been suspended from further 
development.90 It should be noted that doubts have been raised 
about iniparib’s ability to inhibit PARP activity. Although 
initially believed to noncompetitively inhibit PARP1 by 
association with the DNA binding domain, more recent 
studies have failed to demonstrate target inhibition.91 A good 
safety profile was also observed with veliparib (ABT-888; 
Abbott Laboratories, Abbott Park, IL, USA) in combination 
with temozolomide. This was associated with positive early 
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results in metastatic colorectal and BRCA-deficient breast 
cancers, although in advanced melanoma the combination 
was associated with poor response and no progression-free 
or overall survival improvement. Many additional Phase I 
and II trials are  currently underway, in combination with a 
variety of agents, including carboplatin, 5-fluorouracil and 
oxaliplatin, cisplatin and paclitaxel, topotecan, gemcitabine, 
and radiotherapy (reviewed in Davar et al).86 Other PARP 
inhibitors, including orally bioavailable agents, are currently 
also under Phase I investigation.86,92
The data presented above suggest that the clinical util-
ity of PARP inhibitors in combination with chemotherapy 
may be limited in tumors in view of narrow therapeutic 
index. However, evolving preclinical and clinical evidence 
provides compelling data that DNA repair inhibitor use 
could be targeted more effectively by utilizing a synthetic 
lethality strategy.
Synthetic lethality
Synthetic lethality exploits inter-gene relationships where the 
loss of function of either of two related genes is nonlethal, 
but loss of both causes cell death. This offers the potential to 
specifically target cancer cells through inhibition of a gene 
known to be in a synthetic lethal relationship with a mutated 
tumor suppressor gene.93
PARP1 inhibition in BRCA deficiency
The best-characterized synthetic lethality relationship is 
between BRCA mutation and PARP1 inhibition.94–96 PARP1 
plays a role in the BER-related pathway of SSBR. Inhibition 
of SSBR is associated with accumulation of DSBs, which 
can be exploited in a subset of cancers possessing defects 
in DSB repair. BRCA1 and -2 have long been identified as 
tumor suppressors, being mutated in an inherited cancer 
predisposition that increases susceptibility to breast and 
ovarian tumors.97 Both BRCA gene products have a role 
in the HR DNA repair pathway.98 In BRCA-deficient cells, 
loss of effective HR leads to DSB persistence and cell 
death (Figure 2). As heterozygosity at a BRCA allele is 
associated with effective HR, DSB accumulation induced 
by PARP  inhibition specifically occurs only in tumor cells 
with acquired BRCA−/− homozygosity.7,8 Furthermore, loss 
No PARP inhibition PARP inhibition
Normal or BRCA+/−
repaired by HR
BRCA−/−
repaired by BER
BRCA−/−
unrepaired by HR
SSB
formation
BER inhibited
SSB converted to DSB
BER+/
HR+
BER+/
HR+
BER+/
HR−
BER+/
HR−
BER+/
HR−
Normal or BRCA+/−
repaired by BER
Figure 2 Synthetic lethality in BRCA−/− cells upon PARP inhibition. PARP inhibition leads to SSBs. During replication SSBs get converted to DSBs. BRCA−/− cells are deficient 
in HR and hence unable to repair DSBs. DSB accumulation leads to cell death. In cells where PARP is proficient, SSBs are repaired by BER irrespective of BRCA status. There 
is no DSB generation, and cells continue to survive.
Abbreviations: BeR, base excision repair; BRCA, breast cancer susceptibility protein; DSB, double-strand break; HR, homologous recombination; PARP, poly[ADP-ribose] 
polymerase 1; SSB, single-strand break.
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of BRCA2 function has been linked to hyperactivation of 
PARP1 (an observation replicated in loss of other HR factors), 
enhancing the cytotoxic effect.99
PARP inhibition has been hypothesized to cause persis-
tence of endogenously generated SSBs, inducing collapse of 
replication forks and formation of lethal DSBs.100 However, 
the exact mechanism of PARP inhibition has not been fully 
elucidated. Because of its role in the related SSBR pathway, 
PARP1 has occasionally and erroneously been described as 
essential for BER, although knockdown models have dem-
onstrated this to be inaccurate. Unlike many BER factors, 
PARP1 is not essential for viability, nor is it required for repair 
of BER substrates such as alkylation damage – in actuality, 
PARP1 has been demonstrated to reduce BER kinetics.101 
Interestingly, the mode of PARP1 inactivation may impact 
the biological consequences. For example, small interfering 
RNA (siRNA)-mediated PARP1 knockdown does not induce 
significant cytotoxicity in BRCA-deficient cells,7 while small 
molecule inhibition induces SSB accumulation after alkylat-
ing agent treatment and is well documented to be synthetically 
lethal in BRCA-deficient cells.101 This is probably because the 
BER intermediate single-strand nick is a substrate for transient 
PARP1 binding, hence accounting for slowed BER kinetics in 
the presence of PARP1. In this model, PARP inhibitor binding 
may trap PARP1 onto an SSB, whether formed spontaneously, 
exogenously, or by BER.102 As a result, downstream repair 
(whether by SSBR or BER) is prevented, leading to toxic 
DSBs during replication.103 Phase I and II trials of PARP inhib-
itors have demonstrated favorable efficacy and limited toxic-
ity in BRCA-related breast and ovarian cancers.104 An initial 
Phase I study of olaparib in a cohort enriched for BRCA1/2 
mutation carriers demonstrated evidence of in vivo anti-PARP 
activity (using PARP activity measurement in peripheral 
blood mononuclear cells and the surrogate marker of γH2AX 
induction, which accumulates at DSBs) and evidence of 
response in 40% BRCA carriers.96 This led to Phase II trials in 
breast or ovarian cancer associated with BRCA1/2 mutation, 
demonstrating further favorable data suggesting antitumor 
efficacy in this cohort.105,106 Phase III trials in BRCA-mutated 
ovarian cancer are currently planned.107,108 Likewise, Phase II 
investigation of rucaparib in BRCA1/2-mutated breast or 
ovarian cancer demonstrates PARP activity inhibition and 
evidence of tumor response.109 The oral PARP1/2 inhibitor 
niraparib (MK4827; Merck & Co, Inc., Whitehouse Station, 
NJ, USA) has also been evaluated at Phase I to possess an 
acceptable safety profile and probable antitumor activity.110 
“BRCAness” refers to a subset of breast cancers, including 
“triple negative” (estrogen-, progesterone-, and HER2 [human 
epidermal growth factor receptor 2]-negative) and “basal phe-
notype” cancers, that possess molecular and histopathological 
similarity to BRCA-deficient tumors, which have been suc-
cessfully targeted in vitro by PARP inhibition.111,112 Similarly, 
high-grade serous/undifferentiated ovarian cancers (HGSOC) 
are commonly associated with somatic or epigenetic loss 
of BRCA1/2.113 Phase II investigations of olaparib in these 
cohorts initially suggested that there may be a role for PARP 
inhibition in HGSOC,114 although Phase III development was 
terminated after it was deemed unlikely that reported progres-
sion-free survival would translate to an overall benefit.115 It 
should be noted that BRCA deficiency does not translate to 
PARP inhibitor response in all patients, and resistance may 
be a significant problem in future development. Two groups 
independently described the deletion of a previously identified 
BRCA2 mutation in PARP inhibitor-resistant cancer cells that 
led to restoration of the open reading frame, and hence HR 
proficiency.116,117 Furthermore, in BRCA1-deleted cells, loss 
of expression of the HR protein 53BP1 appears to partially 
restore HR competency and abrogate the ATM-dependent 
checkpoint response, limiting the resultant cell cycle arrest 
triggered by DSB accumulation after DNA damaging agent 
exposure.118
Alternative synthetic lethality  
partners for BeR
The discovery of the synthetic lethality relationship between 
PARP1 and BRCA suggests that other tumor-specific defects 
in DSB repair factors may be therapeutically targeted by 
PARP inhibition. Germline mutations in the HR protein 
RAD51D have been identified as conferring susceptibility 
to ovarian cancer and may offer a target for PARP inhibitors 
in a small subset of women.119 Recent evidence suggests 
single agent cytotoxicity of PARP inhibitors in cells with 
reduced expression of ATM, the checkpoint activator that is 
activated by DSBs.120,121 Similar results have been observed 
in cells deficient in expression of the HR protein MRE11,122 
and following in vitro downregulation of Artemis or LIG4, 
both of which function within the NHEJ pathway.123,124 Other 
potential synthetic lethality partners in PARP inhibition 
identified on a high-throughput siRNA screen include the 
DSB-induced checkpoint activator ATR, and a variety of 
factors that have been associated with bypass of stalled rep-
lication or transcription forks, including PCNA, DDB1, and 
XAB2 (XPA-binding protein 2).125 Conversely, SSBR factors 
other than PARP1 are potential synthetic lethality partners in 
DSB repair loss, as observed by the cytotoxicity induced by 
inhibitors of ATM or DNA-PKcs following knockdown of 
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the BER protein XRCC1.126 Given its critical role in BER, 
targeting APE1 also presents a promising alternative. Sultana 
et al121 recently demonstrated that novel small molecule APE1 
inhibitors are able to induce AP site accumulation, DSBs, cell 
cycle arrest, and cytotoxicity in BRCA2- or ATM-deficient 
cells. The synthetic lethality relationship between HR and 
APE1 was confirmed by cytotoxicity observed following 
ATM inhibitor exposure in APE1−/− cells.121
In addition to targeting tumors harboring germline 
defects in HR, Seo et al highlighted a possible treatment 
strategy in sporadic tumors by demonstrating that inhibition 
of APE1 DNA repair function induces targeted cytotoxic-
ity in cell lines cultured in acidic environments.127 Tumor 
microenvironments are commonly acidic and have been 
associated with upregulation of BER proteins, including 
APE1. Conversely, other DNA repair mechanisms, includ-
ing HR, are often downregulated under such conditions.128,129 
Identification of tumors with BER upregulation and HR 
depletion may therefore offer an opportunity to exploit syn-
thetic lethality through APE1 inhibition.
Recent evidence suggests that relationships between 
BER and non-HR DNA repair pathways may hold potential 
for synthetic lethality. For example, 8-oxoguanine base 
lesions, which are induced by metabolic ROS and can cause 
mutagenic GC→TA transversions if unrepaired, may be 
processed by both BER and MMR. Mutations in the MMR 
genes MLH1 or MSH2 are implicated in HNPCC and some 
sporadic colorectal cancers. SiRNA inhibition of the BER 
constituent DNA polymerases β/γ have been demonstrated 
to be selectively lethal in MLH1/MSH2 mutant cell lines, 
suggesting a synthetic lethality relationship.130 It remains to 
be established whether additional factors such as APE1 may 
have a role in this capacity.
Phosphatase and tensin homolog 
mutation as a synthetic lethality target
Phosphatase and tensin homolog (PTEN) is a negative regu-
lator of the anti-apoptotic PI3K/Akt pathway. In addition to 
its inositol phosphatase function, PTEN has recently been 
implicated in the maintenance of genomic integrity.131–136 
On the basis of evidence supporting an HR defect associ-
ated with PTEN mutation,  Mendes-Pereira et al38 tested for 
synthetic lethality in HCT116 colorectal tumor cells trans-
fected with a PTEN-mutant cDNA clone. Homozygosity 
for PTEN mutation was associated with a 20-fold increase 
in sensitivity to PARP inhibitors, which was replicated in a 
panel of commonly cultured tumor cell lines and in mouse 
xenografts. Ectopic expression of wild type PTEN into a 
PTEN-deficient prostate cancer cell line abrogated this effect, 
as did induced expression of a PTEN phosphatase domain 
mutant, suggesting that PTEN’s influence over HR lies out 
with its phosphatase function. Ectopic expression of RAD51 
in a PTEN-deficient cell line was also able to overcome PARP 
inhibitor sensitivity, supporting the proposed link between 
PTEN mutation and reduced RAD51 expression. Similar 
results were demonstrated in endometrioid endometrial carci-
noma, in which PTEN is mutated in up to 80% of patients.137 
In primary PTEN−/− mouse astrocytes, reduced transcription 
of the RAD51 paralogs was associated with sensitivity to 
PARP inhibition,138 while PTEN disruption in colorectal can-
cer cells resulted in reduced MRE11 accumulation at DSBs 
that is also associated with PARP inhibitor sensitivity.139 In 
lung cancer cells, PTEN deficiency potentiated the synergistic 
effect of olaparib and cisplatin combination treatment,140 
while rucaparib sensitized PTEN-deficient prostate cancer 
cells to ionizing radiation,141 with both reports highlighting 
delayed DSB repair kinetics as a likely mechanism.
In the clinical setting, there is anecdotal evidence of suc-
cessful targeting of PTEN deficiency with PARP inhibitor. 
Forster et al142 have presented a case study of usage of the 
PARP inhibitor olaparib in a patient with platinum- responsive 
metastatic endometrioid endometrial adenocarcinoma. 
Treatment was initiated following development of brain 
metastases, on the basis of previous sensitivity with plati-
num agents, which are highly effective in HR deficiency. 
A partial response on magnetic resonance imaging was 
noted at 10 weeks, followed by a progression-free survival 
of 8 months. Tumor biopsy demonstrated PTEN mutation 
with wild type BRCA1 and -2 status.142
However, there is not a consensus regarding the syn-
thetic lethality relationship between PTEN deficiency and 
PARP inhibition. In studies on PTEN-null prostate139 and 
lung143 cancer cells, no enhanced DNA damaging agent or 
PARP inhibitor sensitivity was observed. Furthermore, in a 
Phase I trial in BRCA mutation carriers and sporadic can-
cer, PTEN status did not correlate with antitumor activity 
of niraparib.144
Although PARP inhibitor-induced synthetic lethality in 
PTEN loss has been most widely studied, a recent report from 
Mereniuk et al145 provides evidence that other proteins within 
the SSBR pathways may also be valid targets. A forward 
transfection screen of nearly 7,000 siRNAs was performed 
using A549 lung cancer cells stably depleted of the BER end-
processing enzyme PNKP. This screen identified PTEN as a 
potential synthetic lethal partner, a result then validated by: 1) 
repeat siRNA downregulation of PTEN in PNKP-null MCF7 
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(Michigan Cancer Foundation-7) breast cancer cells; and 2) 
PNKP inhibitor exposure in PTEN-null HCT116  (colorectal) 
and PC3 (prostate) cancer cells. Furthermore, PNKP inhibitor 
treatment in PTEN-deficient cells is associated with accumu-
lation of DSBs, increased apoptosis, and reduced clonogenic 
survival in a manner analogous to published reports of PARP 
inhibition in BRCA mutation. The authors hypothesize that 
PTEN loss is associated with strand-break accumulation 
that may require PNKP-mediated end processing for repair. 
Although a mechanism for strand breakage is not presented, 
sensitivity to PNKP inhibitor could not be abrogated by ecto-
pic RAD51 expression in PTEN-null PC3 cells, in keeping 
with previous reports that synthetic lethality in this cell line 
is not mediated via RAD51 loss.
Developing biomarkers for synthetic  
lethality response
BRCA mutation, although an excellent marker of HR 
deficiency, comprises a small subset of breast and ovarian 
patients. Identification of other synthetic lethality relation-
ships is ongoing, as described above. A number of individual 
DNA repair proteins may therefore be informative regarding 
HR deficiency and synthetic lethality response (reviewed in 
Martin et al).130 An alternative approach to identify patients 
who may benefit from PARP (or BER) inhibition is to use 
gene expression profiles that predict responsiveness. While 
data regarding PARP inhibitor response is currently limited, 
there is a large body of evidence related to anthracycline 
or platinum sensitivity. As both classes are associated with 
DSB induction (via intercalation/topoisomerase inhibition 
and crosslink formation, respectively), it may be predicted 
that response to such agents would also equate to PARP 
inhibitor response. By correlating DNA repair gene expres-
sion microarray data with anthracycline sensitivity in 
triple-negative breast cancer146 and platinum sensitivity in 
epithelial ovarian cancer,147 two groups have been able to 
develop “BRCAness gene signatures” which reproducibly 
predict treatment response. In the ovarian cancer study, this 
was further analyzed in BRCA2-mutated pancreatic cancer 
cell clones to predict for RAD51 foci formation as a marker 
of HR, and for sensitivity to PARP inhibition. Independently, 
RAD51 foci formation in tumor samples has been developed 
as a functional assay for HR status.148 Primary cultures of epi-
thelial ovarian cancer cells from ascitic fluid can be assessed 
for γH2AX and RAD51 foci, which correlate with in vitro 
response to the PARP inhibitor.
Assays have also been developed for monitoring effective 
PARP inhibition on treatment. In multiple clinical trials, PARP 
activity in peripheral mononuclear blood cells (measured as 
cellular levels of poly[ADP]-ribose polymers detected by 
immunofluorescence or enzyme-linked immunosorbent 
assay) has been used as a marker of effective inhibition.149,150 
Surrogate markers, such as comet assay assessment of DNA 
damage level, or DSB estimation by RAD51 or γH2AX foci 
after treatment, have also been used.151 However, it is impor-
tant to note that Phase II studies of olaparib have indicated 
that the maximum tolerated dose, determined by conventional 
dose escalation, may induce a better clinical response than 
the lowest effective PARP inhibitory dose.105,106
Conclusion
DNA repair mechanisms play an essential role in promoting 
genomic stability. Defective DNA repair may predispose to 
cancer. On the other hand, impaired DNA repair capacity 
in cancer cells may influence a favorable response to che-
motherapy and radiotherapy. Recent evidence demonstrates 
that overexpression of DNA repair factors has prognostic 
and predictive significance in cancer patients. More recently, 
DNA repair has emerged as a new area for anticancer drug 
discovery. Use of DNA repair inhibitors in combination 
with chemotherapy or radiotherapy can increase cancer 
cell killing, although combination strategies can lead to 
profound normal tissue toxicity. The strategy of synthetic 
lethality to exploit interrelationships between DNA repair 
pathways appears to bypass many problems associated 
with combination strategies. The recent success of PARP 
inhibitors in BRCA-deficient breast and ovarian cancer 
clearly suggests that additional factors within DNA repair 
are likely to be promising synthetic lethality targets in the 
future and have the potential to transform the therapeutic 
landscape in cancer.
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